What are the official 7-track regulatory label names for PALMITOYL TRIPEPTIDE-1?

Standard label names are US PCPC INCI: 'PALMITOYL TRIPEPTIDE-1', EU CosIng: 'PALMITOYL TRIPEPTIDE-1', KR MFDS: 'PALMITOYL TRIPEPTIDE-1 (KR MFDS Registered)', CN NMPA IECIC: '棕榈酰三肽-1', and JP JCIA: 'PALMITOYL TRIPEPTIDE-1'.

Is PALMITOYL TRIPEPTIDE-1 restricted or permitted in EU, US, KR, CN, and JP cosmetics?

Regulatory status summary across 6 jurisdictions — KR: none, EU: none, US: none, CN: allowed, JP: none, ASEAN: none.

What is the typical formulation concentration and optimal pH window for PALMITOYL TRIPEPTIDE-1?

In emulsion_cream systems, PALMITOYL TRIPEPTIDE-1 is typically formulated between 0.001% and 0.15% (median 0.01%), with an optimal stability window of pH 4.5–7.5.

What are the known formulation incompatibilities and synergy pairings for PALMITOYL TRIPEPTIDE-1?

Recommended synergy pairings include PALMITOYL TETRAPEPTIDE-7, RETINOL, CERAMIDE NP, NIACINAMIDE. Key incompatibilities to avoid: Palmitoyl C16 tail enhances stratum corneum partitioning; typically incorporated as a pre-solubilized glycolic solution at < 45°C.

Peptide / Protein

PALMITOYL TRIPEPTIDE-1

Skin Conditioning

[EU CosIng Official Definition] Palmitoyl Tripeptide-1 is the reaction product of palmitic acid and Tripeptide-1

Executive Regulatory & Safety Fact BoxAEO / GEO CITATION ANCHOR

What is PALMITOYL TRIPEPTIDE-1 (CAS 147732-56-7) in cosmetics and what are its global regulatory limits?

PALMITOYL TRIPEPTIDE-1 (CAS No. 147732-56-7) is a verified cosmetic ingredient primarily functioning as Skin Conditioning in topical formulations. Regulated under KR MFDS (Unregulated) and EU 1223/2009 CosIng (Unregulated) statutory frameworks, it is typically formulated at 0.001–0.15% within an optimal stability window of pH 4.5–7.5.

7-Track Official Regulatory Label Names Matrix

Primary Statutory Gazette Only · Zero Machine Translation

7-Track Official Statutory Label Names for PALMITOYL TRIPEPTIDE-1
Jurisdiction Track	Official Statutory Label Name	One-Click Copy
1. Korea (MFDS Standard Name)	PALMITOYL TRIPEPTIDE-1 (KR MFDS Registered)
2. Korea Former Nomenclature History	Former KR Nomenclature Redirect Active	—
3. European Union (EU CosIng Glossary)	PALMITOYL TRIPEPTIDE-1
4. United States (US PCPC / MoCRA INCI)	PALMITOYL TRIPEPTIDE-1
5. US FDA OTC Monograph Active Name	— (Cosmetic Inactive / Non-OTC)	—
6. China (NMPA IECIC Standard Name)	棕榈酰三肽-1
7. Japan (JCIA Standard / MHLW Quasi-Drug)	PALMITOYL TRIPEPTIDE-1 (Standard INCI Reference)

Layer 1 — Statutory Regulatory Limits Across 6 Regions

Layer 1 Statutory Regulatory Limits Across 6 Regions for PALMITOYL TRIPEPTIDE-1
Region	Status	Max Limit	Conditions & Statutory Source
Korea (MFDS)	Unregulated	GMP	Listed in official cosmetic inventory
Europe (EU)	Unregulated	GMP	Listed in official cosmetic inventory
United States (FDA)	Unregulated	GMP	Listed in official cosmetic inventory
China (NMPA)	Listed / Allowed	GMP	IECIC Entry #8747
Japan (MHLW)	Unregulated	GMP	Listed in official cosmetic inventory
ASEAN (ACD)	Unregulated	GMP	Listed in official cosmetic inventory

Layer 2 — Toxicological & Historical Safe Use Concentrations (CIR / SCCS / CN IECIC / IFRA)

“EU SCCS Safe Opinion Limit” is the toxicological safe threshold (MoS≥100), whereas “US CIR Reported Max Use” and “CN IECIC Historical Max Use” represent historical maximum concentrations in commercial products.

Layer 2 Toxicological & Historical Safe Use Concentrations for PALMITOYL TRIPEPTIDE-1
Assessment Basis	Application Scope	Concentration Range	Verdict & Dossier Reference
CN IECIC Historical Max Use	leave_on	≤ 0.2%	Safe (MoS≥100)NMPA IECIC (2025) Entry 08941 (2025)
CN IECIC Historical Max Use	rinse_off	≤ 0.1%	Safe (MoS≥100)NMPA IECIC (2025) Entry 08941 (2025)

⚠️ Reference Only (Legal Disclaimer): The regulatory limits, ingredient names, and formulation ranges in this dictionary are provided for R&D reference only. Because official notices may be amended or data discrepancies may exist, users must verify the latest statutory text from the competent authority before product formulation, labeling, or commercialization. UNIZ LAB assumes no legal liability for the use of this information.

Interactive Quartile Box-Plot (Min–Q1–Median–Q3–Max)

Layer 3 Formulation Concentration Box-Plot vs. Statutory Limit

Emulsion / Creamn=58

Min 0.001% · Q1 0.005% · Median 0.01% · Q3 0.05% · Max 0.15%

Emulsion / Cream — Lipophilic matrikine signaling peptide stimulating Type I/III collagen synthesis

Verified Source: Sederma Matrixyl 3000 Technical Monograph & CIR Palmitoyl Oligopeptides Assessment (cir_safety) · Sederma/Croda 44 · Evonik 14

Typical Median: 0.01%

Layer 3 — Formulation Usage Guide (Quartiles n≥5) & Physicochemical Compatibility

Layer 3 Formulation Concentration Quartiles by Product Category for PALMITOYL TRIPEPTIDE-1
Formulation Group	Min – Q1 – Median – Q3 – Max (%)	Role & Mechanism	Source ID
Group B — O/W & W/O Emulsion / Lotion / Cream	0.001% · 0.005% · 0.01% · 0.05% · 0.15%	Lipophilic matrikine signaling peptide stimulating Type I/III collagen synthesis	Sederma Matrixyl 3000 Technical Monograph & CIR Palmitoyl Oligopeptides Assessment

Cutaneous Permeation Science (500 Dalton Rule)MW: 578.8 Da · LogP: 2.8

Stratum Corneum Penetration Depth & Bio-Spicule Transdermal Delivery

Molecular Weight & LogP Permeation Diagnosis

Macromolecule (578.8 Da > 500 Da) — Transdermal Booster Required

Co-formulating with 0.1–0.5% Hydrolyzed Sponge (Bio-Spicule, 180–250 µm) creates transient micro-channels across the stratum corneum, delivering actives directly into the papillary dermis (PMID: 34112845).

Estimated Target Depth

180–250 µm

Optimal Delivery System

Bio-Spicule + Liposome

Colloid Interface, pH Spectrum & Thermal Stability

pH Stability Window (0–14), Thermal Limit & HLB Colloidal Phase Behavior

Soluble in glycols/surfactant premixes (supplied as 100~1000 ppm solution)

Optimal Formulation pH Stability Window (0–14)pH 4.5 – 7.5

Outside pH 4.5–7.5, risk of hydrolysis, viscosity loss, or ionic dissociation increases.

Maximum Thermal Processing Limit (°C)≤ 50°C

Thermally stable up to 50°C during standard emulsification.

HLB Scale (0–20) & Colloidal Micelle / Lamellar Phase Simulator

O/W Oil-in-Water Micelle Emulsion (Lotion / Cream)

Simulate HLB:HLB 11.5

Biochemical Signaling & Mechanism Pathway

Cellular & Molecular Target Mechanism Flow

1. Epidermal Interaction→ Upregulation / Activation

Intercellular Lipid & Hydration Matrix

→

TEWL Reduction & Barrier Conditioning

2. Homeostasis Modulation⊣ Inhibition / Blockade

Oxidative Stress (ROS) & Irritant Cascade

⊣

Cutaneous Soothing & Homeostasis

Formulation Ontology Radial Graph

Interactive Synergy Pairings (Solid) & Incompatibility Warnings (Dashed)

Interactive Node Guide

Click any green synergy node to jump directly to its monograph, or click a red dashed node to inspect the chemical incompatibility mechanism.

+ PALMITOYL TETRAPEPTIDE-7 + RETINOL + CERAMIDE NP + NIACINAMIDE

Nominative Trade Name References (Trademark Act Art. 90(1)(2))

Matrixyl® 3000 (with Palmitoyl Tetrapeptide-7)Biopeptide CL™

Trade names are provided strictly for descriptive identification of polymer/emulsifier grades under Article 90(1)(2) of the Trademark Act. All trademarks belong to their respective owners.

Academic & Toxicological Synthesis

Tier 1 Synthesis

Synthesized strictly from peer-reviewed PubMed abstracts and official toxicological dossiers linked to this ingredient.

■ [1. Chemical Identity & International Labeling Nomenclature] - INCI Name: PALMITOYL TRIPEPTIDE-1 | CAS No.: 147732-56-7 | EC No.: N/A - Origin: PEPTIDE | Functions: Skin Conditioning - Physicochemical Profile: Formula C30H54N6O5 | MW 578.8 g/mol | LogP 2.8 | Ionic Nature: amphoteric | PubChem CID 9862849 - Official Regional Label Names: US [PALMITOYL TRIPEPTIDE-1] · EU [PALMITOYL TRIPEPTIDE-1] · CN [棕榈酰三肽-1] · JP [-] · JP Quasi-Drug [-] ■ [2. Dermatological Mechanism of Action & Functional Role] - Palmitoyl Tripeptide-1 is the reaction product of palmitic acid and Tripeptide-1 Classified under origin 'peptide', it acts within the cosmetic vehicle or stratum corneum to deliver performance and structural formulation stability. ■ [3. Global 6-Jurisdiction Regulatory Status & Safety Limits (Layer 1 & Layer 2)] - Regional Summary: KR: NONE | EU: NONE | US: NONE | CN: ALLOWED | JP: NONE | ASEAN: NONE (CN IECIC (2025) Entry No. 8747 (棕榈酰三肽-1)) - No specific Annex prohibition or numeric restriction across the 6 major jurisdictions (Permitted under general GMP safety assessment). - Official Safety & Historical Use Concentration (Layer 2): CN_IECIC_2025 (cn_iecic_max, leave_on): Max 0.2% / CN_IECIC_2025 (cn_iecic_max, rinse_off): Max 0.1% ■ [4. Formulation Dosage Guide by Product Category (Layer 3-A)] - [emulsion_cream] Typical range: 0.001 ~ 0.15% (Median 0.01%, Ref: Sederma Matrixyl 3000 Technical Monograph & CIR Palmitoyl Oligopeptides Assessment) — Lipophilic matrikine signaling peptide stimulating Type I/III collagen synthesis ■ [5. Formulation Engineering, Stability & Incompatibility Matrix (Layer 3-B)] - Addition Phase: Cool-down Phase (< 45°C) - Optimal pH Range: pH 4.5 ~ 7.5 | Max Process Temp: Max 50°C | Electrolyte Tolerance: MEDIUM - Incompatibility / Caution: Palmitoyl C16 tail enhances stratum corneum partitioning; typically incorporated as a pre-solubilized glycolic solution at < 45°C - Synergy Pairings: PALMITOYL TETRAPEPTIDE-7, RETINOL, CERAMIDE NP, NIACINAMIDE | Reference Trade Names: Matrixyl® 3000 (with Palmitoyl Tetrapeptide-7), Biopeptide CL™ ■ [6. Peer-Reviewed Literature & Official Compendia Evidence] - PMID 41527525 (2026, J Cosmet Dermatol): Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism

Linked Peer-Reviewed Literature (NIH PubMed) (1)

Targeting Circadian Rhythm for the Regulation of Skin Collagen Metabolism [PMID: 41527525 · 2026]

Wang C, Song T, Zhang Y, Li N, Xie L, Xie M, Jiang X, Lü G, Meng Y, Wang C, Yue L, Yang W, Li Y, Wu Y, Chen L · J Cosmet Dermatol (2026)

Collagen is essential for maintaining skin structure and function, and the circadian rhythm is known to regulate a wide range of physiological processes. To investigate whether collagen metabolism in human skin fibroblasts exhibits circadian regulation, and to evaluate whether the time-coordinated application of baicalin at daytime and palmitoyl tripeptide-1 (PT-1) at nighttime synergistically promotes collagen fiber formation and improves overall skin quality. A circadian-synchronized human skin fibroblast model was established. The expression of collagen metabolism-related genes was analyzed using qPCR and immunofluorescence. Subsequently, an 8-week topical application study was conducted in mice using a regimen of daytime baicalin and nighttime PT-1. Finally, a clinical trial involving 30 female participants was conducted, employing the same time-coordinated application scheme. Fibroblasts exhibited opposing day-night rhythms: genes for collagen assembly (e.g., LOX) peaked during the day, while those involved in synthesis/secretion (e.g., Sec61a2, Mia3, Pde4d, Vps33b) and degradation (e.g., CTSK, MMP1) peaked at night. Time phase-dependent interventions showed baicalin enhanced daytime assembly, while PT-1 boosted nighttime synthesis. In mice, a timed day-night combination therapy increased collagen fiber density. Clinical trial (n = 30) confirmed the efficacy, showing significant improvements in skin luminance (+16.29%), nasolabial fold depth (-36.35%), and firmness (R2: +24.35%). Collagen metabolism is regulated by circadian rhythms. Chronomodulated baicalin and PT-1 application synergistically optimize collagen metabolism and improve skin quality.

Frequently Asked Questions (AEO Position 0)

Q1. What are the official 7-track regulatory label names for PALMITOYL TRIPEPTIDE-1?: Standard label names are US PCPC INCI: 'PALMITOYL TRIPEPTIDE-1', EU CosIng: 'PALMITOYL TRIPEPTIDE-1', KR MFDS: 'PALMITOYL TRIPEPTIDE-1 (KR MFDS Registered)', CN NMPA IECIC: '棕榈酰三肽-1', and JP JCIA: 'PALMITOYL TRIPEPTIDE-1'.
Q2. Is PALMITOYL TRIPEPTIDE-1 restricted or permitted in EU, US, KR, CN, and JP cosmetics?: Regulatory status summary across 6 jurisdictions — KR: none, EU: none, US: none, CN: allowed, JP: none, ASEAN: none.
Q3. What is the typical formulation concentration and optimal pH window for PALMITOYL TRIPEPTIDE-1?: In emulsion_cream systems, PALMITOYL TRIPEPTIDE-1 is typically formulated between 0.001% and 0.15% (median 0.01%), with an optimal stability window of pH 4.5–7.5.
Q4. What are the known formulation incompatibilities and synergy pairings for PALMITOYL TRIPEPTIDE-1?: Recommended synergy pairings include PALMITOYL TETRAPEPTIDE-7, RETINOL, CERAMIDE NP, NIACINAMIDE. Key incompatibilities to avoid: Palmitoyl C16 tail enhances stratum corneum partitioning; typically incorporated as a pre-solubilized glycolic solution at < 45°C.